Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. | Curr Opin Virol;49: 36-40, 2021 08. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.

Vandyck, Koen; Deval, Jerome.

Affiliation

Vandyck K; Aligos Belgium BV, Leuven, Belgium. Electronic address: kvandyck@aligos.com.
Deval J; Aligos Therapeutics, Inc., South San Francisco, USA. Electronic address: jdeval@aligos.com.

Curr Opin Virol ; 49: 36-40, 2021 08.

Article in En | MEDLINE | ID: mdl-34029993

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Cysteine Proteinase Inhibitors / Coronavirus 3C Proteases / SARS-CoV-2 / COVID-19 Drug Treatment Limits: Animals / Humans Language: En Journal: Curr Opin Virol Year: 2021 Document type: Article Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Cysteine Proteinase Inhibitors / Coronavirus 3C Proteases / SARS-CoV-2 / COVID-19 Drug Treatment Limits: Animals / Humans Language: En Journal: Curr Opin Virol Year: 2021 Document type: Article Country of publication: